Holen Sie sich die Stockscreener-App
2.58
3.01%
-0.08
Handel nachbörslich:
2.56
-0.02
-0.78%
Schlusskurs vom Vortag:
$2.66
Offen:
$2.66
24-Stunden-Volumen:
43,114
Relative Volume:
0.05
Marktkapitalisierung:
$3.79M
Einnahmen:
$502.40K
Nettoeinkommen (Verlust:
$-7.91M
KGV:
-0.2587
EPS:
-9.972
Netto-Cashflow:
$-4.32M
1W Leistung:
+28.36%
1M Leistung:
+1.18%
6M Leistung:
-51.32%
1J Leistung:
-85.16%
1-Tages-Spanne:
$2.5475
$2.6731
1-Wochen-Bereich:
$2.0298
$2.74
52-Wochen-Spanne:
$1.41
$35.99
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
Firmenname
60 Degrees Pharmaceuticals Inc
Sektor
Branche
Telefon
202-327-5422
Adresse
1025 CONNECTICUT AVENUE NW, WASHINGTON
Vergleichen Sie SXTP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
2.58 | 2.96M | 502.40K | -7.91M | -4.32M | -9.972 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
60 Degrees Pharmaceuticals Inc Aktie (SXTP) Neueste Nachrichten
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings - Defense World
Research Analysts’ Recent Ratings Changes for Adaptimmune Therapeutics (ADAP) - Defense World
Weiss Ratings Reiterates Sell (D-) Rating for 180 Degree Capital (NASDAQ:TURN) - Defense World
Live Radar: Track thunderstorms as they move across Southeast Georgia and Northeast Florida (Video) - Spot On Florida
Pre-market Movers: CMRX, CPIX, PBM, CRVO... - RTTNews
VSee Health Launches AI-Powered Telehealth to Reduce Maternal Deaths in Remote Philippines - Quantisnow
Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation - The Manila Times
60 Degrees Pharmaceuticals, Inc. Reports 55% Increase in Q1 2025 Net Product Revenues to $163.6 Thousand - Nasdaq
60 Degrees Pharmaceuticals Announces First Quarter 2025 Results - The Globe and Mail
60 DEGREES PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
AST SpaceMobile (ASTS) Expected to Announce Earnings on Wednesday - Defense World
60 Degrees Pharmaceuticals (SXTP) to Release Quarterly Earnings on Wednesday - Defense World
KORE Group (KORE) to Release Quarterly Earnings on Thursday - Defense World
SPAR Group (SGRP) Expected to Announce Earnings on Wednesday - Defense World
Society Pass (SOPA) Projected to Post Quarterly Earnings on Wednesday - Defense World
Windtree Therapeutics (WINT) to Release Earnings on Wednesday - Defense World
Spero Therapeutics (SPRO) to Release Earnings on Wednesday - Defense World
60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reaffirmed at Weiss Ratings - Defense World
Spartan Delta Corp. (TSE:SDE) Given Average Recommendation of “Strong Buy” by Analysts - Defense World
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
National Bank Financial Weighs in on TSE:ATD FY2025 Earnings - Defense World
FY2025 EPS Estimates for VERA Decreased by Cantor Fitzgerald - Defense World
Evoke Pharma (EVOK) to Release Earnings on Tuesday - Defense World
Legend Biotech (LEGN) Expected to Announce Earnings on Tuesday - Defense World
Best Green Energy Stocks To Research – May 9th - Defense World
PTC Therapeutics (NASDAQ:PTCT) Raised to Strong-Buy at StockNews.com - Defense World
Denny’s Co. (NASDAQ:DENN) Shares Sold by Barclays PLC - Defense World
Brokerages Set Bright Minds Biosciences Inc. (NASDAQ:DRUG) Target Price at $83.25 - Defense World
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
Raymond James Financial Inc. Makes New Investment in NETSTREIT Corp. (NYSE:NTST) - Defense World
60 Degrees Pharmaceuticals Announces 2024 Annual Results - ADVFN
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - ADVFN
60 Degrees Pharmaceuticals (SXTP) Unveils Discrepancies in Babes - GuruFocus
Daily Progress: 60 Degrees Pharmaceuticals Inc (SXTP) Drop -15.51, Closing at 2.67 - DWinneX
60 Degrees Pharmaceuticals Inc (SXTP) Stock: A Comprehensive 52-Week Review - investchronicle.com
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
How is SXTP’s stock performing after recent trades? - uspostnews.com
Shocking Gap: Survey Finds 3 Million Babesiosis Cases While CDC Reports Only 1,834Major Market Opportunity - Stock Titan
Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey - Yahoo Finance
Form 8-KCurrent report - ADVFN
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - ADVFN
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Down 43.2% in March - Defense World
Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com
Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday? - MSN
60 Degrees Pharma's Breakthrough: New Clinical Trials Target Rising Tick-Borne Disease Crisis - Stock Titan
10 Stocks Fall Behind Amid Market Optimism - Insider Monkey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
60 Degrees and Yale to progress tafenoquin for babesiosis - Yahoo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Finanzdaten der 60 Degrees Pharmaceuticals Inc-Aktie (SXTP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):